Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study.
Stefoni S, Midtved K, Cole E, Thervet E, Cockfield S, Buchler M, Toselli L, Pallardo LM, Schena FP, Pilmore H, Kessler M, Chadban S, Carreño CA; MO2ART Study Group. Stefoni S, et al. Among authors: chadban s. Transplantation. 2005 Mar 15;79(5):577-83. doi: 10.1097/01.tp.0000153158.91683.34. Transplantation. 2005. PMID: 15753847 Clinical Trial.
Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
Chadban S, Eris J, Russ G, Campbell S, Chapman J, Pussell B, Trevillian P, Ierino F, Thomson N, Hutchison B, Irish A, Woodcock C, Kurstjens N, Walker R; MyProms AU01 Study Group. Chadban S, et al. Nephrology (Carlton). 2013 Jan;18(1):63-70. doi: 10.1111/nep.12004. Nephrology (Carlton). 2013. PMID: 23110508 Clinical Trial.
Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S; TRANSFORM Investigators. Tedesco-Silva H, et al. Among authors: chadban s. Transplantation. 2019 Sep;103(9):1953-1963. doi: 10.1097/TP.0000000000002626. Transplantation. 2019. PMID: 30801548 Clinical Trial.
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH; C10-002 Study Group. Glotz D, et al. Among authors: chadban s. Am J Transplant. 2019 Oct;19(10):2865-2875. doi: 10.1111/ajt.15397. Epub 2019 May 24. Am J Transplant. 2019. PMID: 31012541 Free PMC article. Clinical Trial.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: chadban s. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
346 results